Key terms
About RAPT
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RAPT news
Apr 12
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Apr 12
1:38am ET
Hold Rating on RAPT Therapeutics Amid Promising Data and Regulatory Uncertainties
Mar 26
8:38pm ET
Rapt Therapeutics price target lowered to $13 from $15 at JPMorgan
Mar 11
12:46am ET
Hold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concerns
Mar 08
6:30am ET
H.C. Wainwright Remains a Hold on RAPT Therapeutics (RAPT)
Mar 08
5:41am ET
Analysts Conflicted on These Healthcare Names: RAPT Therapeutics (RAPT), Eli Lilly & Co (LLY) and Sight Sciences (SGHT)
Mar 07
8:02am ET
Rapt Therapeutics reports Q4 EPS (80c), consensus (86c)
Feb 23
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 22
5:22pm ET
RAPT Therapeutics Clinical Trials Halted by FDA
Feb 22
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 22
4:46am ET
Rapt Therapeutics downgraded to Neutral from Buy at UBS
Feb 21
7:04am ET
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Universal Health (UHS) and RAPT Therapeutics (RAPT)
Feb 21
6:47am ET
Rapt Therapeutics price target lowered to $32 from $42 at Wells Fargo
Feb 21
6:45am ET
Rapt Therapeutics downgraded to Market Perform from Outperform at Leerink
Feb 21
6:07am ET
Rapt Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Feb 21
5:29am ET
Rapt Therapeutics price target lowered to $13 from $35 at Barclays
Feb 20
7:35pm ET
Rapt Therapeutics downgraded to Neutral from Overweight at JPMorgan
Feb 20
4:47pm ET
RAPT Therapeutics Hit by FDA Clinical Trial Hold
Feb 20
10:49am ET
Rapt Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Feb 20
10:32am ET
RAPT Therapeutics (NASDAQ:RAPT) Crashes after FDA Clinical Hold
Feb 20
7:33am ET
Rapt Therapeutics announces clinical hold on studies evaluating zelnecirnon
Feb 16
9:37am ET
UPS upgraded, Nike downgraded: Wall Street’s top analyst calls
Feb 16
6:18am ET
Rapt Therapeutics initiated with an Outperform at Evercore ISI
Feb 14
7:20pm ET
Wolfe starts Rapt at Outperform, sees multiple outperformance opportunities
Feb 14
4:14pm ET
Rapt Therapeutics initiated with an Outperform at Wolfe Research
Jan 15
7:36am ET
3 Best Stocks to Buy Now, 1/15/2024, According to Top Analysts
No recent news articles are available for RAPT
No recent press releases are available for RAPT
RAPT Financials
Key terms
Ad Feedback
RAPT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RAPT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
